| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.0 | 17.6 |
| Profit before tax | -1.3 | -2.3 |
| Net income | -1.3 | -2.3 |
| EPS (diluted, $ a share) | $-0.05 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +7.6% |
|---|---|
| Operating margin | -2.8% |
10-Q filed with the SEC, NASDAQ: DERM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Journey Medical Corp: key numbers
- Share price
- $3.90Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Journey Medical Corp
All →Journey Medical Financial Results
Journey Medical Corporation reported third quarter 2026 financial results, featuring total revenues of $19.0 million, an 8% increase year-over-year. Growth was primarily driven by its oral rosacea treatment, Emrosi, which saw an 84% revenue increase to $9.0 million. The company's net loss narrowed to $1.3 million compared to $2.3 million in the prior-year period.
“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer
“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer